# Morphine (derived from Papaver somniferum)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/morphine-derived-from-papaver-somniferum
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Morphia, Morphinum, Morphine hydrochloride, (-)-Morphine, Morphine (Papaver somniferum alkaloid), Morphine sulfate, MS Contin, Papaver somniferum alkaloid

## Overview

Morphine is a potent mu-opioid receptor (MOR) agonist (Ki ≈ 1.8 nM) that inhibits ascending pain pathways and modulates the perception of pain at both spinal and supraspinal levels. Clinical evidence from decades of controlled trials establishes morphine as the reference standard opioid analgesic for moderate-to-severe acute and cancer pain, providing significant pain relief at intravenous doses of 0.1–0.2 mg/kg and oral doses of approximately 30 mg.

## Health Benefits

- **Severe Acute Pain Relief**: Morphine acts on mu-opioid receptors in the dorsal horn of the spinal cord and the periaqueductal gray to suppress nociceptive transmission, making it the first-line agent for post-surgical, trauma, and acute injury pain management.
- **Cancer Pain Management**: As a WHO Step 3 analgesic, oral and parenteral morphine provides sustained relief in moderate-to-severe cancer pain; extended-release oral formulations allow 12- to 24-hour dosing intervals, improving patient compliance and quality of life.
- **Dyspnea Palliation in Palliative Care**: Low-dose systemic morphine (2–5 mg orally every 4 hours) reduces the subjective sensation of breathlessness in patients with advanced malignancy or end-stage COPD by modulating central respiratory centers and reducing anxiety-driven respiratory drive.
- **Intrathecal and Epidural Analgesia**: Intrathecal morphine concentrates analgesic effects at spinal opioid receptors, enabling effective post-operative pain control at microgram-range doses (0.1–0.3 mg intrathecally) while limiting systemic side effects; delayed respiratory depression may occur 6–12 hours post-administration.
- **Myocardial Infarction Pain and Anxiety**: Intravenous morphine has historically been used in acute MI management to reduce pain, preload, and sympathetic activation, though contemporary evidence has prompted reassessment of routine use due to potential interactions with antiplatelet agents.
- **Chronic Malignant Pain (Opioid Rotation)**: Equianalgesic morphine dosing serves as the reference point for opioid rotation calculations; the oral morphine equivalent (OME) is the universal metric used to compare and convert between all opioid analgesics in clinical practice.
- **Neonatal Abstinence Syndrome and Controlled Withdrawal**: Oral morphine solution is an accepted pharmacotherapy for neonatal opioid withdrawal syndrome, with weight-based dosing protocols (0.03–0.1 mg/kg per dose) used to taper dependence and reduce withdrawal symptoms in affected neonates.

## Mechanism of Action

Morphine binds with highest affinity to the mu-opioid receptor (MOR; Ki ≈ 1.8 nM), a Gi/Go-protein-coupled receptor, producing analgesia by inhibiting adenylyl cyclase, reducing intracellular cAMP, opening inwardly rectifying potassium channels (GIRK), and closing voltage-gated calcium channels — collectively hyperpolarizing neurons and suppressing [neurotransmitter release](/ingredients/condition/cognitive) in pain-processing circuits. At the spinal level, morphine inhibits the release of substance P and glutamate from primary afferent C-fibers in the dorsal horn, while supraspinally it activates descending inhibitory pathways from the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM). Morphine also binds delta-opioid receptors (DOR; Ki ≈ 90 nM) and kappa-opioid receptors (KOR; Ki ≈ 317 nM), though these interactions contribute less to the primary analgesic effect and may modulate mood, sedation, and spinal analgesia to a lesser degree. Morphine undergoes hepatic glucuronidation primarily via UGT2B7 to form morphine-6-glucuronide (M6G), an active metabolite with potent MOR agonist activity, and morphine-3-glucuronide (M3G), a neuroexcitatory metabolite that may antagonize analgesia and contribute to hyperalgesia at high accumulation levels.

## Clinical Summary

The most robustly supported clinical application of morphine is in moderate-to-severe cancer pain, where WHO guidelines and multiple Cochrane reviews (encompassing data from thousands of patients) confirm that oral morphine achieves clinically meaningful pain relief (≥30% reduction on NRS or VAS scales) in approximately 70–90% of patients when titrated appropriately. In post-operative pain, IV morphine at 0.1 mg/kg produces rapid analgesia with onset in 5–10 minutes, and extended-release oral formulations demonstrate sustained 12-hour pain control with similar efficacy to comparable opioids in head-to-head RCTs. Intrathecal morphine (0.1–0.3 mg single-dose) has demonstrated superior post-operative analgesia duration compared to systemic administration in spinal surgery and Caesarean section trials, with number-needed-to-treat (NNT) values of approximately 2–3 for significant pain relief. Confidence in analgesic efficacy is high (evidence tier: Strong); confidence in comparative superiority over other opioids is moderate, as most outcomes reflect equivalence rather than superiority.

## Nutritional Profile

Morphine is a pure alkaloid compound (molecular formula C17H19NO3; molecular weight 285.34 g/mol) and has no relevant macronutrient, micronutrient, or caloric value in pharmacological doses. It is not consumed as a food substance; trace amounts occur naturally in poppy seeds (3.6–261 mg/kg depending on cultivar and processing), which can produce detectable but clinically insignificant plasma morphine levels after ingestion of standard culinary quantities. The pharmacologically active stereoisomer is the naturally occurring (−)-morphine (levo-morphine); the (+)-morphine enantiomer is devoid of opioid receptor activity. Key physicochemical properties relevant to bioavailability include water solubility of approximately 60 mg/mL (as sulfate salt), pKa of 8.0 and 9.9 (for tertiary amine and phenolic OH respectively), and low lipophilicity (log P ≈ 0.9), which limits blood-brain barrier penetration compared to more lipophilic opioids such as fentanyl or heroin.

## Dosage & Preparation

- **Intravenous (IV) Bolus (Adults)**: 0.1–0.2 mg/kg every 2–4 hours as needed; maximum single dose typically 10 mg; onset 5–10 minutes.
- **IV Continuous Infusion (Pediatric/Low Body Weight <50 kg)**: Initial basal rate 0.01 mg/kg/hr; titration range 0.01–0.04 mg/kg/hr based on pain response.
- **Oral Immediate-Release (IR) Tablets or Solution**: Standard adult starting dose 15–30 mg every 4 hours; solution available as 2 mg/mL and 4 mg/mL concentrations for flexible dosing.
- **Oral Extended-Release (ER) Tablets**: 15–200 mg every 8–12 hours (product-dependent); not appropriate for opioid-naive patients at high doses; swallow whole — do not crush or chew.
- **Intrathecal (Spinal) Injection**: 0.1–0.3 mg as single-shot post-operative dose; monitor for delayed respiratory depression for a minimum of 12–24 hours post-administration.
- **Epidural Administration**: 1–6 mg as bolus; 0.1–0.5 mg/hr as infusion; diluted in preservative-free normal saline.
- **Injectable Concentrations Available**: 0.5, 1, 2, 4, 5, 8, 10, 15, 25, and 50 mg/mL morphine sulfate solutions.
- **Oral Solution Stability**: Formulations with glycerin and EDTA (without sodium metabisulfite) retain >99% potency; sodium metabisulfite-containing formulations at pH 6 degrade to 65% potency within 35 days.
- **Standardization**: Pharmaceutical-grade morphine sulfate or morphine hydrochloride is used; purity ≥98% per pharmacopeial standards (USP, BP).

## Safety & Drug Interactions

The most clinically critical adverse effects of morphine include dose-dependent respiratory depression (the primary cause of opioid overdose mortality), constipation (near-universal with chronic use due to peripheral MOR activation in the GI tract), sedation, nausea and vomiting, pruritus (especially with neuraxial administration), urinary retention, and physical dependence with tolerance on repeated dosing. Serious drug interactions include additive CNS and respiratory depression with benzodiazepines, barbiturates, gabapentinoids, alcohol, and other CNS depressants — a combination associated with a markedly elevated risk of fatal overdose; monoamine oxidase inhibitors (MAOIs) are strictly contraindicated due to risk of [serotonin](/ingredients/condition/mood) syndrome and severe hemodynamic instability. Morphine is renally cleared as active glucuronide metabolites (particularly M6G), necessitating dose reduction in renal impairment to prevent metabolite accumulation and prolonged toxicity. Morphine crosses the placenta and is present in breast milk; use during pregnancy carries risk of neonatal opioid withdrawal syndrome (NOWS) and neonatal respiratory depression at delivery, and is reserved for situations where benefit clearly outweighs risk, under close obstetric and neonatal supervision.

## Scientific Research

Morphine is among the most extensively studied analgesics in clinical pharmacology, supported by hundreds of randomized controlled trials, systematic reviews, and meta-analyses accumulated over more than a century of use, earning it an evidence score reflective of robust human data. Cochrane systematic reviews on morphine for cancer pain (e.g., Wiffen et al., multiple iterations) consistently confirm efficacy in the majority of cancer patients, with pooled data from trials involving thousands of participants demonstrating meaningful pain score reductions and tolerability comparable to other strong opioids. Comparative RCTs have established oral morphine as equianalgesic to oral oxycodone and hydromorphone at appropriate dose conversions, and pharmacokinetic studies have thoroughly characterized its volume of distribution (1–6 L/kg), plasma protein binding (20–35%), and renal clearance of active metabolites. Evidence for specific emerging indications such as breathlessness in palliative care is strong but derived from smaller trials (n = 20–100 range), and some historically accepted uses (e.g., routine morphine in acute MI) have been challenged by more recent observational and pharmacodynamic data.

## Historical & Cultural Context

Opium, the crude latex from which morphine is derived, has been used medicinally for at least 5,000 years, with references in ancient Sumerian texts (~3400 BCE) and documented use in Egyptian, Greek, and Roman medicine for pain relief, sleep induction, and antidiarrheal purposes. Morphine itself was first isolated in pure form in 1804–1806 by Friedrich Sertürner, a German pharmacist, who named the compound after Morpheus, the Greek god of dreams — marking the first isolation of a pharmacologically active alkaloid from a plant source and founding the science of alkaloid chemistry. The hypodermic syringe, developed in the 1850s, enabled parenteral morphine administration, which became widely used during the American Civil War and the Franco-Prussian War, leading to the first recognized epidemic of iatrogenic opioid dependence. In the 20th century, the International Narcotics Control Board (INCB) designated morphine as an essential medicine, and the WHO includes it on the Model List of Essential Medicines as the reference opioid analgesic for cancer pain, reflecting its irreplaceable role in global palliative care despite ongoing regulatory challenges around accessibility.

## Synergistic Combinations

Morphine is frequently combined with adjuvant analgesics including NSAIDs (e.g., ketorolac, ibuprofen) and acetaminophen, which act via COX inhibition and central mechanisms distinct from opioid receptors, producing additive-to-synergistic analgesia at lower morphine doses and reducing opioid-related side effects — a strategy supported by multiple post-operative RCTs demonstrating 20–30% opioid dose reduction with multimodal regimens. In neuraxial analgesia, morphine is synergistically combined with local anesthetics (e.g., bupivacaine) and alpha-2 agonists (e.g., clonidine or dexmedetomidine), which act on separate spinal receptor populations to prolong and deepen analgesia beyond what either agent achieves alone. Methylnaltrexone and other peripherally restricted opioid antagonists are used as a functional synergistic pairing to selectively reverse constipation and other peripheral MOR-mediated side effects without compromising central analgesia.

## Frequently Asked Questions

### How does morphine work to relieve pain?

Morphine binds with high affinity (Ki ≈ 1.8 nM) to mu-opioid receptors (MOR), which are Gi-protein-coupled receptors located in the spinal dorsal horn, periaqueductal gray, and limbic system. Activation inhibits adenylyl cyclase, reduces neuronal cAMP, opens GIRK potassium channels, and closes voltage-gated calcium channels, collectively hyperpolarizing pain-transmitting neurons and suppressing the release of substance P and glutamate. This dual spinal and supraspinal action both blocks ascending pain signals and activates descending inhibitory pathways.

### What is the standard dose of morphine for pain management?

For opioid-naive adults, standard oral immediate-release morphine is typically initiated at 15–30 mg every 4 hours, while intravenous dosing is 0.1–0.2 mg/kg every 2–4 hours with a typical maximum of 10 mg per bolus dose. Extended-release oral formulations are dosed at 15–200 mg every 8–12 hours depending on prior opioid exposure and pain severity. Doses must be individualized based on pain intensity, prior opioid tolerance, renal function, and patient weight, particularly in pediatric or low-body-weight populations.

### What are the most dangerous side effects of morphine?

The most life-threatening adverse effect is dose-dependent respiratory depression, which can progress to respiratory arrest and death, particularly when morphine is combined with benzodiazepines, alcohol, or other CNS depressants. After intrathecal administration, delayed respiratory depression may occur 6–12 hours post-dose due to slow rostral spread of morphine in cerebrospinal fluid. Other serious but less immediately fatal risks include physical dependence, constipation leading to bowel obstruction with chronic use, and severe hemodynamic instability when combined with MAO inhibitors.

### Can you take morphine with other medications?

Morphine has several critical drug interactions: concurrent use with benzodiazepines, barbiturates, gabapentinoids, or alcohol causes additive respiratory depression and is associated with a substantially elevated overdose fatality risk. Monoamine oxidase inhibitors (MAOIs) are strictly contraindicated with morphine due to risk of serotonin syndrome and severe cardiovascular instability. Morphine metabolism via UGT2B7 can be affected by rifampicin (inducer, reducing efficacy) and certain antiretrovirals, and it may impair the antiplatelet activity of P2Y12 inhibitors such as ticagrelor by slowing GI absorption.

### Is morphine safe during pregnancy or breastfeeding?

Morphine crosses the placenta and, when used near delivery, can cause neonatal respiratory depression and neonatal opioid withdrawal syndrome (NOWS) in the newborn, which requires monitoring and potentially pharmacological management with weight-based oral morphine tapering protocols. Morphine is detectable in breast milk at low concentrations, and while occasional use may be permissible under close supervision, chronic use is generally discouraged due to risk of sedation and CNS depression in the nursing infant. Use during pregnancy is reserved for situations where severe pain or opioid dependence management clearly outweighs the fetal risk, requiring specialist obstetric oversight.

### What is the difference between morphine sulfate and morphine hydrochloride formulations?

Morphine sulfate and morphine hydrochloride are salt forms that affect bioavailability and administration routes. Morphine sulfate is more commonly used for oral, intravenous, and intramuscular administration due to better stability and formulation options, while morphine hydrochloride may be preferred in certain parenteral applications. Both forms provide equivalent analgesic effects when dosed appropriately, but the choice depends on the clinical context and patient-specific factors.

### Who should avoid morphine or use it with extreme caution?

Patients with severe respiratory depression, acute asthma, severe hypotension, or untreated sleep apnea should avoid morphine due to increased risk of life-threatening complications. Individuals with a history of opioid use disorder, hepatic impairment, renal dysfunction, or those taking monoamine oxidase inhibitors (MAOIs) require careful medical evaluation and monitoring. Elderly patients and those with compromised gastrointestinal function typically require dose adjustments to minimize adverse effects.

### What does clinical evidence show about morphine's effectiveness for different pain types?

Clinical research confirms morphine's high efficacy for acute post-operative, trauma, and cancer pain, with strong evidence supporting its use as a gold-standard analgesic in these conditions. However, evidence suggests morphine is less effective for neuropathic pain compared to acute nociceptive pain, often requiring adjunctive medications. Long-term studies indicate that while morphine remains effective for cancer pain management, tolerance can develop over extended use, necessitating periodic dose adjustments.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*